PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis

PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis

Background For advanced hepatocellular carcinoma (HCC), sorafenib remains the established therapy. PD-1/PD-L1 inhibitors plus antiangiogenic drugs (PIAD) as a new therapeutic approach for advanced HCC is still a subject of clinical debate regarding whether they offer improved treatment outcomes. Thi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun Li MD, Chun Liao MD, Zhaohui Liu MD, Hu Xiong MD, Jing Cai MD, Tiande Liu MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Series:	Technology in Cancer Research & Treatment
Online Access:	https://doi.org/10.1177/15330338241305700
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs
by: Lin Xu, et al.
Published: (2024-12-01)

Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study
by: Yi Peng MD, et al.
Published: (2025-01-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
by: Jennifer Strong, BS, et al.
Published: (2025-02-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles
by: Jun Deng, et al.
Published: (2023-12-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging
by: Linhan Zhang MD, et al.
Published: (2024-06-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
by: Huimin Zou, et al.
Published: (2025-01-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
by: Liu DY, et al.
Published: (2024-11-01)

Sorafenib as Adjuvant Therapy Post–Liver Transplant: A Single-center Experience
by: Hala Hassanain, MD, et al.
Published: (2025-02-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2020-10-01)

Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report
by: Shuangying Zhao, et al.
Published: (2025-01-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
by: Jie Fu, et al.
Published: (2025-01-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

Expanding the PD-L1 Paradigm: A Comprehensive Systematic Review and Meta-Analysis of Scoring Systems and Additional Biomarkers Influencing Immune Checkpoint Inhibitor Outcomes in Breast Cancer
by: Shuangwei Mo MBBS, et al.
Published: (2024-10-01)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
by: Alessandro Russo, et al.
Published: (2020-10-01)

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
by: Jun Lu, et al.
Published: (2024-04-01)

The Prognostic Value of CRP/Alb Ratio in Predicting Overall Survival for Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Combined with Molecular-Targeted Agents and PD-1/PD-L1 Inhibitors
by: Huang X, et al.
Published: (2025-01-01)

Rhus Verniciflua Stokes Inhibits PD-1 Expression and Induces Anticancer Effects by Enhancing T Cell Function
by: Seoyoung Kim PhD, et al.
Published: (2025-01-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials
by: Weiming Zhang, et al.
Published: (2024-12-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-11-01)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
by: Huimin Zhao, et al.
Published: (2025-02-01)